Helix BioPharma Corp (TSE:HBP) (OTCMKTS:HBPCF) (FRA:HBP) CEO Heman Chao tells Proactive it will receive up to C$10 million in financing from New York based institutional investment fund Lind Global Macro Fund, LP through the issuance of convertible securities. Chao says the first tranche of C$3.5 million is expected to be issued on or around May 12, with the second tranche of up to an additional C$6.5 million available to be received thereafter. The funds will be used towards advancing its Phase lb/ll pancreatic cancer clinical study.
Helix BioPharma Corp raises C$10M in institutional investor funding from Lind Partners
